Use of Technetium-99m-Pyrophosphate Single-Photon Emission Computed Tomography/Computed Tomography in Monitoring Therapeutic Changes of Eplontersen in Patients With Hereditary Transthyretin Amyloid Cardiomyopathy
Journal
Journal of the American Heart Association
Journal Volume
13
Journal Issue
2
Pages
e030512
Date Issued
2024-01-16
Author(s)
Yu, An-Li
Chen, Yi-Chieh
Wu, Yuan-Kun Aden
Chou, Chia-Hung
Hsueh, Hsueh-Wen
Lee, Ming-Jen
Hsu, Chia-Hua
Chao, Chi-Chao
Abstract
Hereditary transthyretin amyloid cardiomyopathy (hATTR-CM) is a progressive and fatal disease. Recent evidence indicates that bone scintigraphy may serve as a tool to monitor the effectiveness of hATTR-CM treatment. The objective of this study was to examine how eplontersen therapy influences the semiquantitative uptake of technetium-99m-pyrophosphate in individuals diagnosed with hATTR-CM.
Subjects
99mTc‐pyrophosphate; eplontersen; hereditary transthyretin amyloidosis; single‐photon emission computed tomography/computed tomography
SDGs
Type
journal article